Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

For Immediate Release

Press Release

Sanders Sends Letter to Biden Urging Delay in Medicare Premiums Increase

Citing outrageous costs and safety concerns around Alzheimer’s drug, Sanders calls for Medicare to negotiate drug prices.

Sen. Bernie Sanders (I-Vt.) on Friday sent a letter to President Biden urging his administration to delay an increase in Medicare premiums coming in 2022 following the U.S. Food and Drug Administration’s (FDA) approval of the outrageously expensive Alzheimer’s drug Aduhelm, which costs $56,000 per person each year.

“This is a perfect example of why Medicare should be negotiating drug prices with the pharmaceutical industry,” wrote Sanders. “Unless you take action soon, the standard monthly Medicare Part B premium paid by some 57 million beneficiaries will increase by 14.55 percent (from $148.50 to $170.10) beginning next year. This $21.60 a month increase in Medicare premiums would be the largest in the 56-year history of Medicare and it could not come at a worse time for older Americans all over this country who are struggling economically.”

Biogen, the manufacturer of Aduhelm, has set the price of this Alzheimer’s drug at $56,000 even though the Institute for Clinical and Economic Review, an independent non-profit organization, has estimated that the maximum price of this drug should be no higher than $3,000-$8,400.

As Biogen seeks to make exorbitant profits, 10 out of 11 experts on the FDA’s advisory committee voted against approving Aduhelm. The Veterans Health Administration has announced that it would not be covering Aduhelm due to safety concerns and the “lack of evidence of a robust and meaningful clinical benefit,” and at least a half a dozen private health insurance companies have also decided not to cover Aduhelm.

Despite the concerns in the scientific community and the outrageous price, over the summer the FDA approved Aduhelm for use in the United States. The result is that Medicare, which covers all FDA-approved drugs, will increase Part B premiums on January 1, 2022 in order for the program to afford the new treatment. As a result of the approval in June, three members of the FDA’s advisory committee resigned in protest.

In his letter, Sanders urged the Biden Administration to immediately prevent the Medicare Part B premium increase, delay Medicare’s approval for use of Aduhelm until it is deemed safe and effective, and take executive action to reinstate and expand the reasonable pricing clause requiring drug makers that receive federal funding to charge reasonable prices for prescription drugs and treatments – a policy that ended in 1995.

Sanders wrote, “In my view, it would be absolutely unacceptable to force 57 million senior citizens to pay $11.50 more a month in Medicare premiums due to Biogen’s greed and thirst for massive profits for a drug that has not been proven to be effective by the scientific community and has been rejected for coverage by the Veterans Health Administration and at least a half a dozen private health insurance companies in the United States. It would be equally unacceptable to force seniors suffering from Alzheimer’s disease to come up with a 20 percent co-payment of $11,200 out of their own pockets for Aduhelm – which is precisely what they would have to pay if Biogen is allowed to charge $56,000 for this drug.”

Sanders concluded, “Biogen’s $56,000 price of Aduhelm is the poster child for how dysfunctional our prescription drug pricing system has become. The notion that one pharmaceutical company can raise the price of one drug so much that it could negatively impact 57 million senior citizens and the future of Medicare is beyond absurd. With Democrats in control of the White House, the House and the Senate we cannot let that happen.”

Read the full letter here.

'A No-Brainer': Lawmakers Urge Pelosi to Hold Vote on Stock Trading Ban

"Perhaps this means some of our colleagues will miss out on lucrative investment opportunities," said House members in a bipartisan letter. "We don't care."

Jessica Corbett ·

Virginia Schools Sue Youngkin Mandate Making Masks Optional

The Republican governor wants to allow parents to decide whether their children should wear masks to school to mitigate Covid-19 transmission—guidance at least 58 school districts have no plans to follow.

Julia Conley ·

US Puts Troops on Standby as War Tensions Over Ukraine Mount

The U.K. threatens "lightning war" as military forces mobilize in eastern Europe.

Andrea Germanos ·

Advocacy Group Urges Pfizer to Combat Paxlovid Inequality

"Help end the pandemic this year around the world," one advocate told Pfizer. "Not just in a handful of rich countries."

Kenny Stancil ·

260+ Companies Demand 'Big, Bold Action' on Clean Energy

"The time to act is now," the firms wrote in a letter to Chuck Schumer and Nancy Pelosi.

Andrea Germanos ·

Support our work.

We are independent, non-profit, advertising-free and 100% reader supported.

Subscribe to our newsletter.

Quality journalism. Progressive values.
Direct to your inbox.

Subscribe to our Newsletter.

Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit | Privacy Policy
Common Dreams Logo